

Christian Brander

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2657221/christian-brander-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

6,800
citations

37
h-index

82
g-index

98
ext. papers

7,542
ext. citations

8
avg, IF

4.77
L-index

#	Paper	IF	Citations
92	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.. <i>EBioMedicine</i> , 2022 , 78, 103956	8.8	0
91	Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1032-1040	5.1	0
90	Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8 T cell antiviral responses. <i>Cell Reports</i> , 2021 , 35, 109103	10.6	0
89	Considerations for successful therapeutic immunization in HIV cure. <i>Current Opinion in HIV and AIDS</i> , 2021 , 16, 257-261	4.2	1
88	In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. <i>PLoS Pathogens</i> , 2020 , 16, e1008607	7.6	6
87	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 17, 418-428	6.4	5
86	Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. <i>Frontiers in Immunology</i> , 2020 , 11, 418	8.4	13
85	Novel Approaches Towards a Functional Cure of HIV/AIDS. <i>Drugs</i> , 2020 , 80, 859-868	12.1	12
84	TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses. <i>Journal of Immunology</i> , 2020 , 205, 3348-3357	5.3	1
83	SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. <i>Vaccines</i> , 2020 , 8,	5.3	5
82	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 9981-9990	11.5	23
81	HIVconsV Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). <i>Frontiers in Immunology</i> , 2020 , 11, 823	8.4	28
80	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?. <i>Frontiers in Immunology</i> , 2020 , 11, 573928	8.4	1
79	Strong sex bias in elite control of paediatric HIV infection. <i>Aids</i> , 2019 , 33, 67-75	3.5	14
78	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. <i>Trials</i> , 2019 , 20, 361	2.8	17
77	Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. <i>PLoS ONE</i> , 2019 , 14, e0212347	3.7	2
76	Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. <i>Vaccines</i> , 2019 , 7,	5.3	7

75	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019 , 11, 65-80	11.3	30
74	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. <i>Vaccines</i> , 2019 , 7,	5.3	13
73	Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery. <i>Journal of Immunology</i> , 2019 , 202, 441-450	5.3	12
72	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. <i>Journal of Virology</i> , 2019 , 93,	6.6	15
71	HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency. <i>Frontiers in Microbiology</i> , 2018 , 9, 1066	5.7	6
70	HIV T-Cell Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1075, 31-51	3.6	12
69	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. <i>PLoS ONE</i> , 2018 , 13, e0208345	3.7	4
68	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. <i>Aids</i> , 2018 , 32, 2533-2545	3.5	50
67	Benzyl-2-Acetamido-2-Deoxy-β-D-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy. <i>Frontiers in Immunology</i> , 2017 , 8, 2010	8.4	5
66	A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. <i>Microbes and Infection</i> , 2017 , 19, 69-74	9.3	7
65	Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. <i>PLoS ONE</i> , 2017 , 12, e0176418	3.7	25
64	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. <i>PLoS ONE</i> , 2017 , 12, e0184929	3.7	12
63	Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). <i>Aids</i> , 2017 , 31, 321-332	3.5	27
62	Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals. <i>PLoS ONE</i> , 2016 , 11, e0147571	3.7	2
61	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. <i>Aids</i> , 2016 , 30, 553-62	3.5	6
60	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. <i>Journal of Translational Medicine</i> , 2015 , 13, 60	8.5	60
59	Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. <i>PLoS Pathogens</i> , 2015 , 11, e1004658	7.6	38
58	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1833-42	5.1	47

57	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. <i>Cytotherapy</i> , 2015 , 17, 1280-91	4.8	4
56	Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. <i>Journal of Infectious Diseases</i> , 2015 , 211, 936-46	7	11
55	Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. <i>Retrovirology</i> , 2015 , 12, 80	3.6	1
54	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. <i>Aids</i> , 2015 , 29, 1309-18	3.5	6
53	FARMS: A New Algorithm for Variable Selection. <i>BioMed Research International</i> , 2015 , 2015, 319797	3	2
52	Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. <i>Science</i> , 2015 , 348, aaa0698	33.3	231
51	Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1. <i>Journal of Virology</i> , 2015 , 89, 4015-9	6.6	17
50	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. <i>PLoS ONE</i> , 2015 , 10, e0141456	3.7	17
49	Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells. <i>Journal of Virology</i> , 2014 , 88, 12992-3004	6.6	39
48	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A194-A194	1.6	
47	Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. <i>Journal of Immunology</i> , 2014 , 193, 1988-97	5.3	105
46	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3057-60	5.1	25
45	Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. <i>PLoS ONE</i> , 2014 , 9, e86254	3.7	42
44	Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. <i>PLoS ONE</i> , 2014 , 9, e87334	3.7	11
43	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. <i>Journal of Translational Medicine</i> , 2013 , 11, 48	8.5	3
42	HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-B2/B2. <i>Immunobiology</i> , 2013 , 218, 543-7	3.4	5
41	Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients. <i>European Journal of Immunology</i> , 2013 , 43, 1545-54	6.1	1
40	HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. <i>PLoS ONE</i> , 2013 , 8, e60245	3.7	36

39	CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. <i>PLoS ONE</i> , 2012 , 7, e29717	3.7	103
38	Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. <i>PLoS Pathogens</i> , 2012 , 8, e1002529	7.6	270
37	Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. <i>Journal of Virology</i> , 2012 , 86, 12643-54	6.6	42
36	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011 , 9, 208	8.5	124
35	High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. <i>Journal of Virology</i> , 2011 , 85, 9334-45	6.6	99
34	Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences. <i>PLoS ONE</i> , 2011 , 6, e17969	3.7	18
33	Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. <i>Journal of Experimental Medicine</i> , 2010 , 207, 61-75	16.6	43
32	Virological, Immune and Host genetics Markers in the Control of HIV Infection. <i>Disease Markers</i> , 2009 , 27, 105-120	3.2	43
31	HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. <i>PLoS ONE</i> , 2009 , 4, e6687	3.7	131
30	Virological, immune and host genetics markers in the control of HIV infection. <i>Disease Markers</i> , 2009 , 27, 105-20	3.2	25
29	HLA class I supertypes: a revised and updated classification. <i>BMC Immunology</i> , 2008 , 9, 1	3.7	463
28	Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. <i>Journal of Virology</i> , 2008 , 82, 3147-53	6.6	47
27	Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. <i>Journal of Virology</i> , 2008 , 82, 5594-605	6.6	122
26	Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. <i>Aids</i> , 2008 , 22, 447-56	3.5	27
25	Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. <i>PLoS ONE</i> , 2008 , 3, e1424	3.7	133
24	Extensive HLA class I allele promiscuity among viral CTL epitopes. <i>European Journal of Immunology</i> , 2007 , 37, 2419-33	6.1	106
23	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. <i>Nature Medicine</i> , 2007 , 13, 46-53	50.5	824
22	Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes. <i>Journal of Virology</i> , 2007 , 81, 4904-8	6.6	29

21	Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. <i>Journal of Virology</i> , 2007 , 81, 12382-93	6.6	274
20	Increased sequence diversity coverage improves detection of HIV-specific T cell responses. <i>Journal of Immunology</i> , 2007 , 179, 6638-50	5.3	30
19	Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 183-8	4.2	4
18	Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. <i>Journal of Virology</i> , 2006 , 80, 3122-5	6.6	254
17	Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. <i>Journal of Immunology</i> , 2006 , 176, 4094-101	5.3	136
16	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. <i>Nature Immunology</i> , 2006 , 7, 173-8	19.1	193
15	The challenges of host and viral diversity in HIV vaccine design. <i>Current Opinion in Immunology</i> , 2006 , 18, 430-7	7.8	41
14	Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". <i>Journal of Translational Medicine</i> , 2005 , 3, 20	8.5	33
13	Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. <i>Journal of Immunology</i> , 2005 , 175, 4355-62	5.3	46
12	Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. <i>Journal of Virology</i> , 2004 , 78, 4463-77	6.6	157
11	IL-8 responsiveness defines a subset of CD8 T cells poised to kill. <i>Blood</i> , 2004 , 104, 3463-71	2.2	73
10	Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. <i>Journal of Immunological Methods</i> , 2003 , 275, 19-29	2.5	120
9	Gradual adaptation of HIV to human host populations: good or bad news?. <i>Nature Medicine</i> , 2003 , 9, 1359-63	9.63	60
8	Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. <i>Blood</i> , 2002 , 100, 698-700	2.2	30
7	Evolution and transmission of stable CTL escape mutations in HIV infection. <i>Nature</i> , 2001 , 412, 334-8	50.4	488
6	Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2001 , 193, 169-80	16.6	334
5	Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. <i>Journal of Experimental Medicine</i> , 2001 , 193, 375-86	16.6	400
4	Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. <i>Journal of Experimental Medicine</i> , 2001 , 193, 181-94	16.6	241

- | | | | |
|---|--|------|-----|
| 3 | Efficient generation of human T cells from a tissue-engineered thymic organoid. <i>Nature Biotechnology</i> , 2000 , 18, 729-34 | 44.5 | 127 |
| 2 | Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide. <i>European Journal of Immunology</i> , 1993 , 23, 3217-23 | 6.1 | 22 |
| 1 | Discrimination of human CD4 T cell clones based on their reactivity with antigen-presenting T cells. <i>European Journal of Immunology</i> , 1992 , 22, 2295-302 | 6.1 | 25 |